Design, Development and Evaluation of Anti-Inflammatory Drug Etodolac by Crystallo-Co-Agglomeration Technique

Abstract

Etodolac is used to assist alleviate the symptoms of rheumatoid arthritis, osteoarthritis, and mild to moderate discomfort. However, these medications' bioavailability and absorption in the body are problematic. The design and assessment of crystal co-agglomerates made with different poloxamer concentrations are the focus of the current investigation. The study's goal was to improve the drug's solubility and pharmacological properties while also increasing its absorption in the body to improve therapeutic response. When the parameters of the manufactured Crystalo-Co-Agglomerates were assessed, it was discovered that the 5% batch was ideal due to its superior flow ability, highest drug content, and enhanced dissolution properties. It was shown that the creation of crystal co-agglomerates was an effective method for enhancing the different characteristics that can lower the likelihood of drug metabolism and provide improved therapeutic response and stability.